## **IN THE CLAIMS**

This listing of claims replaces all prior versions, and listings, in this application.

Claims 1-9 (canceled)

10. (currently amended) A mutant of a parent filamentous <u>fungus</u> fungal cell, the parent <u>filamentous fungus</u> organism having a preference for non-homologous recombination (NHR), wherein the ratio of NHR/HR is decreased in the mutant as compared to said ratio in said parent <u>filamentous fungus</u> organism measured under the same conditions and wherein the mutant is deficient in a gene encoding a component involved in NHR, and/or has a decreased level of a component involved in NHR.

Claim 11 (canceled)

- 12. (previously presented) The mutant according to claim 10, wherein the mutant is, preferably inducibly, deficient in at least one of the following genes: *hdfA* or homologues thereof, *hdfB* or homologues thereof, or both, and/or has, preferably inducibly, a decreased amount of at least one of the proteins encoded by these genes.
- 13. (previously presented) The mutant according to claim 10, wherein in the genome of the organism a gene involved in NHR has been replaced by a non-functional variant.
- 14. (previously presented) The mutant according to claim 10, wherein the mutant has an increased level of a component involved in HR.
- 15. (currently amended) The mutant according to claim 10, wherein the mutant is a recombinant mutant in which a gene is completely inactivated by recombination.
- 16. (currently amended) A filamentous <u>fungus</u> <u>fungal having a preference for non-homologous recombination (NHR)</u>, which has a ratio <u>of NHR to homologous</u>

recombination (NHR/HR) less than 50, preferably less than 10, even more preferably less than 1, and most preferably less than 0.001.

- 17. (currently amended) The <u>mutant filamentous fungus</u>-according to claim 10, <u>which is</u> transformed with a DNA construct comprising a DNA sequence comprising a gene of interest encoding a polypeptide of interest.
- 18. (currently amended) The <u>mutant filamentous fungus</u>-according to claim 10, wherein the filamentous fungus is an *Aspergillus*, *Penicillium* or *Trichodermaspecies* species.
- 19. (currently amended) The <u>mutant filamentous fungus</u>-according to claim 18, wherein the <u>filamentous fungus Aspergillus</u>-is [[an]] Aspergillus niger or an Aspergillus oryzae species.
- 20. (currently amended) The <u>mutant filamentous fungus</u>-according to claim 18, wherein the <u>filamentous fungus Penicillium</u> is [[a]] *Penicillium chrysogenum* or *Penicillium citrinum*-species.
- 21. (currently amended) A method Method for producing a polypeptide of interest using the mutant according to claim 17, comprising: wherein the filamentous fungus of claim 10 is used
- (a) culturing the mutant under conditions conducive to expression of said DNA sequence encoding the polypeptide and
- (b) recovering the polypeptide of interest.
- 22. (withdrawn-currently amended) <u>A method</u> Method for producing a metabolite using the mutant according to claim 15, comprising: wherein the filamentous fungus of claim 10 is used
- (a) culturing the mutant under conditions conducive to produce the metabolite and
- (b) recovering the metabolite.

23. (withdrawn-currently amended) <u>The method</u> Method according to claim 22, wherein the metabolite is a carotenoid compound or a beta-lactam compound.

Claims 24-25 (canceled)

- 26. (new) A mutant of a parent filamentous fungus with increased frequency of targeted integration of a polynucleotide to a predetermined genomic site, the parent filamentous fungus having a preference for non-homologous recombination (NHR), said mutant being obtainable by steering an integration pathway towards homologous recombination (HR), wherein the steering comprises providing a mutant which is deficient in a gene encoding a component involved in NHR, and/or has a decreased level of a component involved in NHR.
- 27. (new) The mutant according to claim 26, wherein the steering comprises providing a mutant which is, preferably inducibly, deficient in at least one of the following genes: *hdfA* or homologues thereof, *hdfB* or homologues thereof, or both, and/or has, preferably inducibly, a decreased amount of at least one of the proteins encoded by these genes.
- 28. (new) The mutant according to claim 26, wherein the steering comprises providing a mutant in which a gene involved in NHR has been replaced by a non-functional variant.
- 29. (new) The mutant according to claim 26, wherein the steering comprises adding an excess of small double stranded polynucleotides to the polynucleotide to be integrated.
- 30. (new) The mutant according to claim 26, wherein the steering comprises decreasing the activity of at least one protein active in the NHR by adding an inhibitor of said protein(s).

- 31. (new) The mutant according to claim 26, wherein the mutant has an increased level of a component involved in HR.
- 32. (new) The mutant according to claim 26, wherein the mutant has a ratio NHR/HR less than 50, preferably less than 10, even more preferably less than 1, and most preferably less than 0.001.
- 33. (new) The mutant according to claim 26, wherein the mutant is a recombinant mutant in which a gene is completely inactivated by recombination.
- 34. (new) The mutant according to claim 26, which is transformed with a DNA construct comprising a DNA sequence comprising a gene of interest encoding a polypeptide of interest.
- 35. (new) A method for producing a polypeptide of interest using the mutant according to claim 34, comprising:
- (a) culturing the mutant under conditions conducive to expression of said DNA sequence encoding the polypeptide and
- (b) recovering the polypeptide of interest.
- 36. (new) The fungus according to claim 16, wherein the fungus has a ratio NHR/HR less than 10.
- 37. (new) A method for producing a metabolite using the mutant according to claim 33, comprising:
- (a) culturing the mutant under conditions conducive to produce the metabolite and
- (b) recovering the metabolite.
- 38. (new) The method according to claim 22, wherein the metabolite is a carotenoid compound or a beta-lactam compound.